Interpretation of medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse event related to administration of antiresorptive or antiangiogenic medications. With the increasing usage of bone-modifying agents in cancer therapy, the incidence of MRONJ enhanced gradually, which affects the life quality of patients and interferes with cancer therapy. In 2019, Multinational Association of Supportive Care in Cancer (MASCC), International Society of Oral Oncology (ISOO) and American Society of Clinical Oncology (ASCO) convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations on practices in the prevention and management of MRONJ in patients with cancer. The present article made an interpretation of Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline so as to provide clinicians with diagnostic and therapeutic approaches for cancer patients with MRONJ.

药物相关性颌骨坏死（medication-related osteonecrosis of the jaw，MRONJ）是与抗骨吸收药物或抗血管生成药物等相关的颌骨不良反应。随着癌症治疗过程中骨改良药物使用的增加，MRONJ的发生率越来越高，不仅干扰肿瘤的正常治疗，也影响患者的生命质量。2019年，癌症支持疗法多国学会（Multinational Association of Supportive Care in Cancer，MASCC）/国际口腔肿瘤学会（International Society of Oral Oncology，ISOO）及美国临床肿瘤协会（American Society of Clinical Oncology，ASCO）对2003至2017年间癌症患者的MRONJ相关文献进行了分析，共纳入系统评价、随机对照试验、前瞻性研究及回顾性研究等132项，形成《MASCC/ISOO/ASCO药物相关性颌骨坏死临床实践指南》。本文就该指南进行解读，旨在为诊治癌症患者的MRONJ提供参考。.